LivaNova PLC, a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (“FDA”) approvals for its latest Vagus Nerve Stimulation Therapy® (“VNS Therapy”) System, which consists of the SenTiva™ implantable generator and the next-generation VNS Therapy Programming System for the treatment of patients with drug-resistant epilepsy.
